<code id='38025F999B'></code><style id='38025F999B'></style>
    • <acronym id='38025F999B'></acronym>
      <center id='38025F999B'><center id='38025F999B'><tfoot id='38025F999B'></tfoot></center><abbr id='38025F999B'><dir id='38025F999B'><tfoot id='38025F999B'></tfoot><noframes id='38025F999B'>

    • <optgroup id='38025F999B'><strike id='38025F999B'><sup id='38025F999B'></sup></strike><code id='38025F999B'></code></optgroup>
        1. <b id='38025F999B'><label id='38025F999B'><select id='38025F999B'><dt id='38025F999B'><span id='38025F999B'></span></dt></select></label></b><u id='38025F999B'></u>
          <i id='38025F999B'><strike id='38025F999B'><tt id='38025F999B'><pre id='38025F999B'></pre></tt></strike></i>

          knowledge

          knowledge

          author:focus    Page View:22812
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Readout Newsletter: The latest from Bristol, Sarepta, and Novartis
          Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

          CourtesyBristolMyersSquibbWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetour

          read more
          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more

          CDC recommends rationing of RSV shot due to shortages

          Inanewhealthalert,theCDCsaidcliniciansshouldprioritizeavailableBeyfortusdosesforbabiesathighestriskf